- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03970642
Video Directly Observed Therapy (VDOT) to Improve Medication Adherence (NARSAD)
January 24, 2022 updated by: UConn Health
Video Directly Observed Therapy (VDOT) to Improve Medication Adherence Among Depression Patients
Due to the lack of human resources, it is impossible to monitor patients' medication adherence objectively or in-person by observation like tuberculosis programs worldwide do.
The feasibility and patient acceptance of the innovative video-based directly observed therapy (VDOT) approach for improving medication adherence among tuberculosis patients has been demonstrated through studies in the United States as well as internationally (7).
Medication adherence among VDOT users has been found to be comparable to in-person directly observed treatment (91% vs 95%) among patients in New York (8).
In this clinical research project, we will test the feasibility, acceptance and effectiveness of an innovative mobile-based behavioral intervention to improve medication adherence and depression symptoms among patients suffering from depression.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a randomized prospective study utilizing Video Directly Observed Therapy (VDOT), which is a novel means of remotely observing patients ingesting medications using videos sent from the patients' smartphone application.
The VDOT mobile phone application called SureAdhere was developed and found to be feasible and acceptable for monitoring daily treatment of active tuberculosis in San Diego, CA (R21-AI088326; PI: R. Garfein).
For testing the feasibility, acceptance and effectiveness of VDOT application (app) SureAdhere among depression patients, we will conduct a two-arm randomized controlled trial for which a maximum of 100 patients will be recruited (50 patients in study group; 50 patients in control group).
Informed consent will be obtained prior to the start of study activities.Randomization will be performed using a computer generated randomization program assigning a random group to each consecutive study participant.
This will be performed prior to the study and stored in a list with participant numbers.
Those assigned to the control group will receive care as usual.
Those assigned to study group will receive assistance in installing the SureAdhere app on their own smartphone.
If they did not own a smartphone, a loaned smartphone with internet service plan and preinstalled SureAdhere mobile phone application will be provided to them if available.
The SureAdhere app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server.
The study group subjects will receive a pin for their individualized log-in through a text message on their phone.
They will be trained on how to use the application to send videos through a training video and handouts provided to them.
Study staff will be available to answer any questions or concerns about the SureAdhere app.
In case of technical issues, study staff will gather information about the concerns and then get input from the customer support team at SureAdhere, Inc. to resolve the issues.
The study group subjects will receive individualized text reminders on their phone prior to each dose of their depression medicine.
They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit.
Research staff will regularly monitor videos using a password protected website and document each medication dose.
Outcomes data will be obtained through self-report questionnaires at three time points: baseline, about 6 weeks and about 3 months and from the patient medical records.
The baseline questionnaire will be conducted after the informed consent and will collect information about demographic characteristics (i.e.
date of birth, sex, race, ethnicity, type of residence- house vs apartment own vs rent, type of insurance), medication adherence (using ASK-20 Medication Adherence questionnaire) and depression symptoms (using Patient Health Questionnaire-9).
Both these validated survey tools are available for public use.
The follow-up questionnaires sent to the subjects will obtain additional information regarding technology acceptance from the participants in the study group only.
From all subjects, the follow-up questionnaires will gather information about medication adherence and depression symptoms.
Patient medical records and VDOT video review will be used to obtain an objective measure of medication adherence, comorbidities (Elixhauser co-morbidity score) and clinical outcomes.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- UConn Health Psychiatry practice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Eligible patients will be English speaking
- >=18 years old
- diagnosed with depression and currently prescribed oral antidepressant medication
- own a mobile phone and active phone plan capable of receiving text messages.
Exclusion Criteria:
- Non-English speakers, minors (<18 years old)
- patients diagnosed with bipolar disorder (patient may be included if the study team determines that the historical diagnosis of bipolar disorder was inaccurate)
- visual or cognitive disabilities and/or terminal illness
- patients with any clinically significant medical or psychiatric condition, as deemed by the investigator, that can affect their ability to participate in the protocol, including primary psychotic disorder, and active suicidal intent or plan at the time of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention group
The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine.
They will receive the video directly observed therapy smartphone app.
Research staff will be able to monitor these medication adherence video on a password protected server linked to the app.
Upto 50 patients will be randomly assigned to this group.
|
The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine.
They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit.
The app will automatically upload the video to a HIPAA compliant server.
Research staff will regularly monitor videos using a password protected website and document each medication dose.
|
NO_INTERVENTION: Control
The control group will receive current standard of care.
Upto 50 patients will be randomly assigned to this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in medication adherence
Time Frame: The questionnaire will be administered at baseline, 6 weeks and 3 months.
|
The change in medication adherence during the study period will be determined using the ASK-20 questionnaire.
The ASK-20 questionnaire includes 20 questions, each with a likert response from 1 to 5 with 1 representing excellent and 5 representing poor medication adherence.
|
The questionnaire will be administered at baseline, 6 weeks and 3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depression symptoms
Time Frame: The questionnaire will be administered at baseline, 6 weeks and 3 months.
|
The PHQ9 questionnaire will be used to examine the change in depression symptoms.
This 9-question scale has a four point likert scale with 1 being the least and 4 representing the highest depression symptoms.
|
The questionnaire will be administered at baseline, 6 weeks and 3 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 27, 2019
Primary Completion (ACTUAL)
April 15, 2020
Study Completion (ACTUAL)
April 15, 2020
Study Registration Dates
First Submitted
May 29, 2019
First Submitted That Met QC Criteria
May 29, 2019
First Posted (ACTUAL)
May 31, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 1, 2022
Last Update Submitted That Met QC Criteria
January 24, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 19-136-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Video directly observed therapy
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Mattienne van der KampNot yet recruiting
-
Johns Hopkins UniversityUniversity of Cape TownTerminated
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Chinese University of Hong KongGuangzhou Institute of Respiratory DiseaseCompleted
-
Nationwide Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsNot yet recruitingSickle Cell DiseaseUnited States
-
Massachusetts General HospitalFenway Community Health; National Institute of Drug AbuseRecruitingHiv | Substance Use DisordersUnited States
-
San Francisco Department of Public HealthNational Institute on Drug Abuse (NIDA)RecruitingHIV InfectionsUnited States
-
University of California, San DiegoCompletedTuberculosis | Latent Tuberculosis InfectionUnited States